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Cytochrome b5 and NADH-cytochrome b, reductase are integral membrane proteins with cytosolic active domains and short membrane anchors, 
which are inserted post-translationally into their target membranes. Both are produced as different isoforms, with different localizations, in 
mammalian cells. In the rat, the reductase gene generates two transcripts by an alternative promoter mechanism: a ubiquitous mRNA coding for 
the myristylated membrane-bound form, and an erythroid mRNA which generates both the soluble form and a nonmyristylated membrane-binding 
form. The available evidence indicates that the ubiquitous myristylated form binds to the cytosolic face of both outer mitochondrial membranes 
and ER. In contrast, two genes code for two homologous forms of cytochrome b5, one of which is found on outer mitochondrial membranes, the 
other on the ER. The gene specifying the ER form probably also generates an erythroid-specific mRNA by alternative splicing, which codes for 
soluble cytochrome bS. Possible molecular mechanisms responsible for the observed locahzations of these different enzyme isoforms are discussed. 
Endoplasmic reticulum; Outer mitochondrial membrane; Protein myristylation; Alternative promoter 
1. INTRODUCTION 
A large number of endoplasmic reticulum (ER) en- 
zymes, many of which are involved in lipid and drug 
metabolism, have a cytosolically exposed active site and 
only a small lumenal domain (or possibly no lumenal 
amino acid residues at all) so that large portions of their 
polypeptide chain must not be translocated across the 
ER membrane. The biosynthesis of this class of pro- 
teins, their mechanism of targeting to the ER and of 
correct insertion into the phospholipid bilayer, repre- 
sents an important aspect of ER biogenesis. 
Studies on the biosynthesis of ER enzymes with cy- 
tosolically exposed active domains have shown that dif- 
ferent pathways of insertion are followed by different 
proteins. As summarized in Table I, of the 11 proteins 
studied to date, five (all lacking a cleavable signal se- 
quence), were shown to share the co-translational or 
Signal Recognition Particle (SRP)-dependent pathway 
mechanism with translocated proteins (for review see 
[ll]), while the other 6 are inserted by an alternative 
pathway. In Table I, we have indicated this alternative 
pathway as ‘post-translational’, based mainly on the 
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finding that the corresponding mRNA is recovered with 
free polysomes in cell fractionation experiments, in con- 
trast to the situation for the co-translational, SRP-de- 
pendent proteins, the mRNA of which is always found 
associated with tightly bound polysomes. If the list of 
Table I will turn out to be representative, over half of 
the ER proteins with cytosolically located active do- 
mains might use such alternative mechanism(s) for 
membrane insertion. 
We have chosen cytochrome b, (cyt b,) and NADH- 
cytochrome b5 reductase (reductase) as models for the 
study of post-translational insertion of ER membrane 
proteins, because they are well characterized integral 
membrane proteins, with opposite membrane topogra- 
phy. In the ER, cyt b, has a C-terminal hydrophobic 
membrane anchor (23 residues), and an active, cy- 
tosolic, N-terminal domain of = 100 residues [121, while 
the reductase has an N-terminal myristylated anchor 
(24 residues) and a C-terminal active domain of = 275 
residues, which is oriented to the cytosol [13]. A good 
reason to use these proteins as models is that both are 
present as different isoforms with different localizations 
in mammalian cells. The availability of similar, but dif- 
ferently located forms of these proteins should be very 
helpful in the investigation of post-translational target- 
ing pathways to intracellular membranes. 
We will first give a little information on the structure 
and function of the ER forms of the two enzymes, and 
then review our work on the subcellular distribution of 
the isoforms and on the biogenetic relationships be- 
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tween them. Finally, we will discuss the interactions of 
these enzymes with membranes and possible targeting 
mechanisms. 
2. STRUCTURE AND FUNCTION OF THE ER 
FORMS OF CYT b5 AND NADH-CYT b, RE- 
DUCTASE 
Both cyt 6, and reductase belong to protein families 
with members in evolutionarily distant organisms. Cyt 
b, belongs to a family of hemoproteins characterized by 
the so-called ‘cytochrome b, fold’ [14], while reductase 
is a member of a recently discovered flavoenzyme family 
of dehydrogenases-electron transferases [15]. 
Proteins of both families have diverse intracellular 
localizations. They may be cytosolic (as for plant 
NADH-nitrate reductase), peripherally associated with 
a membrane (as for chloroplast ferredoxin-NADP’ re- 
ductase), or integrated in the membrane by a short hy- 
drophobic stretch with the hydrophilic active domain 
exposed to the cytoplasm (as for mammalian reductase 
and cyt b,). Members of both families are often found 
as domains of larger multicenter redox enzymes, sug- 
gesting that both cyt b,- and reductase-like proteins 
arose early in evolution and that they were used as 
building blocks for the construction of more compli- 
cated proteins by gene fusion events (reviewed in [16]). 
In mammalian cells (with the exception of erythro- 
cytes - see below) cyt 6, and reductase have been con- 
verted to membrane-bound enzymes, with their active 
domains exposed at the cytosol. The localization of this 
electron transport chain on membranes concentrates 
the components to a two-dimensional space, and is 
thought to promote a discreet orientation of the active 
domains, which would facilitate interaction of the en- 
zymes with each other [17]. This interaction is thought 
not to involve the formation of stable complexes be- 
tween the two enzymes [18]. Cyt b5 is known to donate 
its electrons to a variety of acceptors involved in diverse 
aspects of lipid metabolism, such as fatty acid desatura- 
tion [19] and cholesterol biosynthesis [20]. Cyt b, can 
also accept electrons from an alternative reductase, 
NADPH-cyt P-450 reductase [19], and participate in 
drug metabolism, interacting with some (but not all) 
forms of cyt P-450 [21]. Thus, while reductase has only 
one acceptor on the ER membrane, cyt b, is promiscu- 
ous, using multiple acceptors and also more than one 
donor. In all these interactions, the same negatively 
charged surface area surrounding the exposed heme 
edge of cyt b5 appears to be involved, with formation of 
complementary charge pairs between carboxylate 
groups of that region and appropriately spaced amino 
groups at the surface of the various acceptors or donors 
[22 and references therein]. 
3. ISOFORMS OF CYT b5 AND OF NADH-CYT b, 
REDUCTASE AND THEIR SUBCELLULAR 
DISTRIBUTION 
While cyt b, and reductase are present in most mam- 
malian cells as membrane-bound proteins, both en- 
zymes exist also in soluble form in erythrocytes. In the 
erythrocyte cytoplasm, soluble cyt b, reduces methemo- 
globin, and the reductase-cyt b, system constitutes the 
most important enzymatic system for the maintenance 
of hemoglobin in the reduced state. Erythrocyte reduc- 
tase deficiency is the most common cause of hereditary 
methemoglobinemia n man [23]. 
In addition to these soluble isoforms and to the ‘clas- 
sical’ microsomal enzymes, novel membrane-bound 
isoforms of cyt b, and of the reductase have been discov- 
Table I 
Mode of insertion* of mammalian ER proteins with cytoplasmically oriented active domains 
Co-translational Post-translational 
Sarcoplasmic reticulum Ca*’ ATPase 
Ill** 
Cytochrome P-450 (phenobarbital-induced) 
121 
Epoxide hydrolase 
[31 
Hydroxymethylglutaryl-Coenzyme A reductase 
[41 
NADPH-cytochrome P-450 reductase 
131 
Microsomal aldehyede dehydrogenase 
[51 
Cytochrome b5 
1361 
Heme oxygenase 1 
171 
NADH-cytochrome bS reductase 
K31 
a subunit SRP receptor 
[91 
stearyl CoA desaturase 
UOI 
* The evidence on the mode of insertion of the listed proteins is based on the identification of their site of 
synthesis (free or bound polysomes) and/or on the demonstration of SRP-dependence or independence in 
cell-free systems. 
**Because of limitations in the length of the bibliography for FEBS Letters mimreviews, the list of references 
quoted here is not complete. 
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ered, the biogenesis and significance of which will be 
discussed here. 
rn~toc~~~driaI membrane forms 
Initial comparison of the primary structures of the 
soluble and microsomal forms of bovine cyt b5 demon- 
strated that the soluble isoform was identical to the 
NH,-terminal, cytoplasmic catalytic domain of the mi- 
crosomal enzyme (residues l-97) [24]. This suggested 
that the two isoforms were products of the same gene. 
The authors also proposed that the soluble form might 
derive from the microsomal enzyme by proteolytic re- 
lease of the catalytic domain from the hydrophobic 
COOH-terminal membrane anchor during erythropoi- 
esis. However, when sequence comparison was carried 
out in other mammalian species, it was found that the 
C-terminal residue of the soluble form had no counter- 
part in the microsomal enzyme (e.g. ref [25]). These data 
gene 
transcripts 
translation 
pl-OdUCts 
intracellular 
destination 
NADH-cyt bs reductase cytochrome bg 
suggested that soluble and microsomal forms are gener- 
ated from separate mRNAs. Indeed, Giordano and 
Steggles [26] recently isolated a cDNA from human 
reticulocytes which codes for soluble cyt bS and which 
has a 24 nt insertion between codons 96 and 97 of the 
corresponding liver transcript. The inserted sequence 
starts with two in-frame codons followed by a stop 
codon. Since the rest of the sequence of this cDNA is 
identical to the liver transcript, the data strongly suggest 
that the mRNAs coding for the microsomal and soluble 
forms of cyt b5 are generated from the same gene by 
tissue-specific alternative splicing, as illustrated in Fig. 
1. 
It has been known for many years that outer mito- 
chondrial membranes (OMM) contain spectrally detect- 
able cyt 6,, and it was believed that microsomal cyt b5 
accounted also for the outer mitochondrial form. In- 
deed, anti-cyt b, antibodies recognized the cytochrome 
on OMM in immuno-electron microscopy [27] and en- 
ER OMM 7 Cytosol 
Rg. 1. Schematic representation of the biogenesis and intracellular targeting of rat NADNcyt 6s reductase and cyt b, isoforms. The figure illustrates 
the following points: (i) one gene generates the known reductase isoforms by a combination of alternative promoters and alternative initiation of 
translation, while two genes are involved in the generation of the ER and outer mitochondrial membrane (OMM) forms of cyt b5; (ii) while the 
same (myristylated) form of reductase appears to be targeted both to ER and to OMM, the cyt b, forms on these two membranes are products 
of different genes; (iii) the soluble anchorless forms of the reductase and cyt b5 differ from the ER forms at the N-terminus and C-terminus 
respectively, and are generated by an alternative promoter mechanism combined with initiation of translation from a downstream AUG in the 
case of the reductase, and by alternative splicing at the 3’ end of the gene in the case of cyt b,. The symbols in the left part of the figure (reductase 
gene) represent: Pu, housekeeping promoter; Pa, erythroid promoter; stippled rectangle, exon which contains the coding sequence for the 
myristylation consensus; checkered rectangle, reticulocyte-specific exon, encoding 13 non-charged aminoacids; open rectangle, first exon common 
to the 2 transcripts (only the 5 portion of the gene is shown); U, ubiquitous transcript; E, erythroid transcript; AUG in boldface, initiation codon 
in optimal context for translation initiation; AUGs in normal printing, initiation codons in suboptimal contexts for initiation. The symbols at the 
right of the figure (cyt 6, genes) represent: P, and P2, unidentified promoters of genes coding for cyt b, isoforms (both genes are shown as dashed 
lures to indicate that they have not yet been cloned and characterized); open rectangle, exon common to ubiquitous and erythroid transcript, coding 
for the C-terminal portion of the cytosolic domain (the 5’ border is not known, and is therefore represented as a dashed line); f&d rectangle, 
altematively spliced exon, which is included in the erythroid transcript, and whose third codon is a te~ination codon; striped rectangle, exon coding 
for the C-terminal membrane-anchor of the ER form of cyt b5; U, E, and U?, ubiquitous, erythroid, and probably ubiquitous transcripts, 
respectively. See text for further explanations. 
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zyme inhibition experiments [28]. Subsequently, how- 
ever, a tryptic hemopeptide with b5 spectral characteris- 
tics was purified from mitochondria, sequenced [29], 
and found to be different from the microsomal tryptic 
hemopeptide, with which it shared = 60% of its se- 
quence. Antibody inhibition studies suggested that the 
newly characterized hemopeptide was derived from an 
OMM isoform of cyt b5 (OM-cyt b,) [30]. Since the 
sequence difference between microsomal and OM- cyt 
b, are distributed throughout the hemopeptides, the re- 
sults of Lederer et al. [29] also indicated that these two 
isoforms are products of different genes. 
An interesting question opened by the discovery of 
OM-cyt b5 was whether any microsomal cyt b5 was on 
the OMM at all. Indeed, the two isoforms would be 
expected to cross-react with polyclonal antibodies, thus 
casting doubt on all previous immunological studies 
[27,28,30]. An exclusion of microsomal cyt b, from 
OMM would be in contrast with the widely held belief 
that cyt b5 can insert into any phospholipid bilayer, 
thanks to its C-terminal insertion sequence (e.g. [l]). 
D’Arrigo et al. [31] have recently investigated this 
problem, using antipeptide antibodies monospecific for 
each of the two cyt b, isoforms. They first used the 
anti-OM-cyt b5 antibody to identify the holocytochrome 
as a 23 kDa polypeptide, bound to the OMM in an 
alkali and urea-resistant fashion. They then used the 
two antibodies to probe Western blots of well-charac- 
terized subcellular fractions. Quantitative analysis re- 
vealed that OM-cyt b5 was not present on ER mem- 
branes, while microsomal cyt b5 was present on OMM 
at extremely low concentrations, less than 5% its con- 
centration on ER membranes. The analysis also showed 
that most (if not all) of the spectrally detectable cyt b5 
on the surface of mitochondria is the OM-specific form, 
which, however, is expressed at lower concentration on 
its target membrane than its microsomal counterpart is 
on the ER membrane. These data suggest hat novel 
post-translational targeting mechanisms result in the 
exclusion of microsomal cyt b5 from OMM and direct 
it to the ER. In agreement with our conclusion, it has 
recently been shown that microsomal cyt b,, overex- 
pressed in COS cells, co-distributes with microsomal 
markers in cell fractionation experiments [32]. 
3.2. Myristylated and non-myristylated isoforms of 
NADH-cyt b, reductase 
The membrane anchor of microsomal reductase is 
N-myristylated [13]. The first 7 residues of the primary 
translation product (which contains the initiator Met) 
constitute the signal for myristylation, a co-transla- 
tional modification catalysed by a cytoplasmic enzyme 
(for review see [33]. The myristylation consensus se- 
quence is followed by a group of 3 residues, of which 
the third one is basic, and a subsequent stretch of 14 
uncharged amino acids. 
As in the case of cyt b5, also for the reductase, amino 
acid sequence analysis revealed that the soluble form 
was identical to the cytoplasmic catalytic domain of the 
membrane-bound myristylated enzyme, and it was sug- 
gested that the soluble enzyme was generated by post- 
translational proteolysis during erythrocyte maturation 
[34]. Recently, however, we have shown [35] that soluble 
reductase is encoded by a separate mRNA, which is 
generated from the reductase gene by an alternative 
promoter mechanism (see Fig, 1). The first exon of the 
reductase gene contains the 5’ non-coding sequence, the 
initiator AUG, and only 6 codons which specify the 
myristylation consensus (stippled rectangle in reductase 
gene in Fig. 1). This exon is preceded by a housekeeping 
promoter. It is expressed ubiquitously and spliced to the 
third exon of the gene. 
A specific erythroid mRNA is generated by initiation 
of transcription from exon 2 (checkered rectangle in 
Fig. l), which is preceded by an erythroid-specific pro- 
moter. Thus, the codons specifying the myristylation 
consensus can be excluded or included in the transcript 
in a tissue-specific manner. The erythroid mRNA was 
found to be bifunctional (Fig. 1). It generates two pol- 
ypeptides: a minor product, which is an N-terminally 
extended form of the reductase and which starts from 
the first initiation codon (product with checkered rec- 
tangle at its N-terminus in Fig. l), and a major product 
which begins from a downstream AUG. The generation 
of these two products can be explained by ‘leaky” scan- 
ning [36]. The first initation codon is weak, so that a 
large proportion of small ribosomal subunits bypass it 
and initiate translation at the downstream AUG. This 
downstream AUG is in the common portion of the two 
reductase transcripts and its use leaves the entire mem- 
brane anchor out of the polypeptide product, with gen- 
eration of the soluble form of the reductase. It is not 
used in the ubiquitous transcript, because the first 
AUG, which precedes the myristylation consensus, is in 
a strong context for initiation (bold-faced AUG in ubiq- 
uitous reductase transcript of Fig. 1) and does not per- 
mit ‘leaky’ scanning. 
One unexpected finding of this study [35] was the 
existence of the hitherto undescribed third reductase 
isoform (the N-terminally extended erythroid polypep- 
tide). This isoform has at its N-terminus 12 uncharged 
reticulocyte-specific residues in addition to 17 residues 
of the membrane anchor of myristylated reductase (res- 
idues 7-23 of the myristylated form). Thus, it has a 
hydrophobic, non-myristylated N-terminal region, and, 
indeed, it was found that it interacts with microsomes 
in vitro. Since reductase is present on the plasma mem- 
brane of rat erythrocytes [37], it is tempting to speculate 
that the N-terminal anchor of this third isoform has 
specific targeting information which differs from that of 
the anchor of the ubiquitously expressed myristylated 
enzyme. 
In liver cells, reductase is present on OMM as well as 
on ER membranes ([38] and references therein). West- 
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ern blot analysis of well characterized liver subcellular 
fractions showed that the reductase is most concen- 
trated in OMM, followed by ER membranes, and that 
it is present in low concentration or absent in other 
membranes [38]. In contrast to the situation for cyt b,, 
the OMM and microsomal forms of the reductase ap- 
pear to be the same protein. They have the same appar- 
ent molecular weight, generate identical peptide maps, 
and are immunologically indistinguishable [39]; they 
also have the same amino acid composition and are 
both myristylated [40]. Moreover, only one reductase 
transcript was detected in rat liver, and results of South- 
ern blotting of rat genomic DNA were consistent with 
the presence of a single reductase gene [41]. Thus, it 
appears that the same protein inserts into two biogenet- 
ically unrelated membranes. Nontheless, it cannot at 
present be excluded that minor differences exist between 
the mitochondrial and ER forms, which have escaped 
the analyses carried out so far. 
What is the function of the OMM reductase-cyt b5 
system? The microsomal acceptors of cyt b5 have not 
been found on OMM, but Ito et al. [42] showed that 
OM cyt b, is involved in ascorbate regeneration from 
semidehydroascorbate. Why this system has been 
placed on the surface of mitochondria rather than on 
the ER is an open question. 
Fig. 1 summarizes the available information on the 
biogenenesis and subcellular localization of cyt b, and 
reductase isoforms reviewed above. 
4. INTERACTIONS WITH MEMBRANES AND 
POSSIBLE TARGETING MECHANISMS 
What are the molecular mechanisms which result in 
the subcellular distribution of cyt b, and reductase 
isoforms described above? While it is likely that OM cyt 
b5 shares its targeting mechanism with other OMM pro- 
teins (for review see [43]), the presumptive post-transla- 
tional targeting pathways to the cytosolic face of the ER 
remain to be discovered. 
A first point of ignorance concerns the exact topogra- 
phy of the membrane anchors. Although it is known 
that they penetrate deeply into the interior of the bi- 
layer, there is no general agreement as to whether they 
span the entire bilayer, or whether they are confined to 
the cytoplasmic leaflet in a hairpin conformation (e.g. 
[12,44-46] and references therein). In the latter case, the 
insertion of the enzymes in the target membrane would 
not involve the translocation of any amino acid resi- 
dues. 
Another point of confusion has arisen from in vitro 
binding studies to liposomes. Early experiments howed 
that both microsomal cyt b, and reductase could associ- 
ate in an active form with preformed liposomes. These 
results lent support to the idea that proteins like cyt b, 
and reductase can opportunistically insert into any bi- 
layer also in vivo. Later, however, it was observed that 
74 
both proteins, bound to preformed liposomes, although 
interacting directly with the phospholipid fatty acyl 
chains, were in a ‘loose’, exchangeable conformation 
different from that of the endogenous tightly bound 
proteins [17,47]. Thus, the in vitro binding experiments 
carried out in the past (e.g. [l]) which made no distinc- 
tion between the two types of interaction, are of doubt- 
ful significance. 
Future research will be directed to uncovering on the 
one hand the signals and, on the other hand, the fea- 
tures of the membranes involved in these as yet uninves- 
tigated targeting pathways. The availability of cDNA 
clones for cyt 6, and reductase, and the possibility of 
expressing wild-type, mutant or chimaeric forms of the 
enzymes in vivo and in vitro, should be very helpful in 
the search for putative targeting signals. Using this ap- 
proach, Mitoma and Ito [32] have recently reported 
that, in COS cells, the carboxy-terminal 10 amino acid 
residues of microsomal cyt b5 are necessary for its tar- 
geting to the ER. Vergeres and Waskell[46] found that 
a mutant rat microsomal cyt b5, in which Ala-131 and 
Glu-132 (at positions -2 and -3 from the COOH termi- 
nus) were changed to lysines, remained normally mem- 
brane associated. Further work with mutants is re- 
quired to nail down the targeting sequence of micro- 
somal cyt b5. No experiments with mutant forms of the 
reductase have been carried out yet. An interesting 
point to investigate is the role of the N-terminally bound 
myristic acid. Covalently bound myristic acid is thought 
to be involved in protein-protein interactions [33], as, 
for instance, in the case of the interaction of the 
myristylated tyrosine kinase p60’~“” with a 32 kDa re- 
ceptor [48]. Another point of interest in the targeting of 
the reductase is whether the same molecular feature 
targets it to OMM and ER membranes or whether two 
distinct signals coexist in the same protein. 
Concerning the target membranes involved in recog- 
nition, it seems reasonable to search for specific protein 
receptors involved in targeting, since lipids alone are not 
sufficient for physiologically relevant binding of the en- 
zymes (see above). To do this, it will be necessary to 
establish cell-free systems which distinguish between 
physiologically relevant and irrelevant binding. There 
are two ways in which these putative protein receptors 
could work. A ‘stoichiometric’ receptor would work by 
binding with high affinity to the post-translationally 
targeted protein, forming a stable complex with it. A 
‘catalytic’ receptor would act by somehow facilitating 
insertion of the post-translationally targeted protein, 
which would then dissociate from the receptor and re- 
main stably integrated in the bilayer. 
In conclusion, mammalian cells use a combination of 
genetic tricks (alternative genes, alternative promoters, 
alternative splicing, alternative initiation codons) to 
produce differently localized isoforms of cyt b, and cyt 
b, reductase. The mechanisms by which these, and other 
membrane proteins with similar topography, reach their 
Volume 325, number 1,2 FEBS LETTERS June 1993 
target membranes from their site of synthesis on free 
polysomes, remain to be elucidated. 
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